N/A
N=5
Mobile Contingency Management for Marijuana and Tobacco Cessation
Cigarette Smoking · Marijuana Abuse
Bottom Line
View on ClinicalTrials.gov: NCT02869451 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcome: Primary: Number of Participants Who Self-report Prolonged Abstinence From Smoking — 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- bupropion (Drug); transdermal nicotine patch (Drug); Nicotine polacrilex (Drug); nicotine lozenge (Drug); counseling for marijuana and smoking cessation (Behavioral); mobile contingency management (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- May 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Self-report Prolonged Abstinence From Smoking |
— | — |
| PRIMARY Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine |
— | — |
| PRIMARY Number of Participants Who Self-report Prolonged Abstinence From Marijuana Use |
— | — |
| PRIMARY Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Oral Fluid |
— | — |
| SECONDARY Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking |
1 | — |
| SECONDARY Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Marijuana |
2 | — |
| SECONDARY Number of Participants Who Report 30 Day Point Prevalence Abstinence From Marijuana |
1 | — |
| SECONDARY Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking |
1 | — |
| SECONDARY Number of Participants Who Report 7 Day Point Prevalence Abstinence From Smoking |
— | — |
| SECONDARY Number of Participants Who Report 7 Day Point Prevalence Abstinence From Marijuana |
3 | — |
| SECONDARY Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine |
— | — |
| SECONDARY Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Salivary Cotinine |
3 | — |
| SECONDARY Change From Baseline in Number of Days Per Week of Cannabis Use |
-3.4 | — |
| SECONDARY Proportional Change in Days of Cannabis Use From Pre-quit to 6 Month Follow-up (Entire Group) |
28 | — |
| SECONDARY Change in Number of Cigarettes Smoked Per Week Compared to Pre-quit |
-37.8 | — |
| SECONDARY Proportional Change in Days Smoked From Pre-quit to 6-month Follow up (for Entire Group) |
80 | — |
| SECONDARY Percentage of Missing Mobile Contingency Management Video Recordings |
33.9 | — |
| SECONDARY Number of Missed Behavioral Counseling Sessions |
— | — |
| SECONDARY Number of Voluntary Withdrawals From the Project |
— | — |
Summary
The purpose of this pilot project is to pilot-test a combined cannabis and smoking cessation treatment. The intervention combines mobile technology with behavioral strategies, counseling, and medications.
Eligibility Criteria
Inclusion Criteria
- report 40 or more days of cannabis use in the past 90 day;
- have smoked at least seven cigarettes in the past seven days;
- have been smoking for at least the past year;
- can speak and write fluent conversational English;
- are between 18 and 70 years of age; and
- are willing to make an attempt to quit both cannabis and tobacco smoking.
Exclusion Criteria
- expected to have unstable medication regimen during the study;
- currently receiving non-study behavioral treatment for cannabis use disorder or smoking;
- myocardial infarction in past six months;
- contraindication to NRT with no medical clearance;
- use of other forms of nicotine such as cigars, pipes, or chewing tobacco with unwillingness to stop use of these forms;
- current pregnancy;
- primary psychotic disorder or current manic episode;
- substance use disorder (other than cannabis or nicotine) within the preceding three months; or
- current imprisonment or psychiatric hospitalization.
Data sourced from ClinicalTrials.gov (NCT02869451). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.